Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Historical Holders from Q3 2020 to Q3 2025

Symbol
PRLD on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
44,162,869
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
27,161,835
Holdings value
$39,111,943
% of all portfolios
0%
Number of holders
45
Number of buys
12
Number of sells
-30
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 23.5% $8,010,575 10,269,968 Baker Bros. Advisors LP 12 Jun 2025
Vaddi Krishna 13.8% +43% $4,926,336 +$699,706 6,397,839 +16.6% Vaddi Krishna 31 Mar 2025
INCYTE CORP 9.9% $6,295,859 4,372,124 INCYTE CORP 03 Nov 2025

Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 27,161,835 $39,111,943 +$249,044 $1.44 45
2025 Q2 27,187,955 $21,995,839 -$2,401,932 $0.8094 49
2025 Q1 30,289,302 $23,267,043 -$2,260,767 $0.7680 56
2024 Q4 32,136,788 $40,964,573 -$12,964,360 $1.28 60
2024 Q3 35,754,682 $74,021,916 +$3,111,676 $2.07 69
2024 Q2 33,917,161 $129,220,239 -$1,353,555 $3.81 59
2024 Q1 34,197,005 $162,095,049 -$2,346,403 $4.74 56
2023 Q4 34,725,223 $148,268,893 -$6,317,081 $4.27 55
2023 Q3 36,614,209 $113,138,241 +$1,036,814 $3.09 57
2023 Q2 36,273,689 $163,232,997 +$31,250,061 $4.50 52
2023 Q1 31,510,272 $179,609,477 +$1,734,926 $5.70 54
2022 Q4 31,178,634 $188,300,136 -$4,385,760 $6.04 59
2022 Q3 31,821,580 $210,332,653 -$5,208,246 $6.61 50
2022 Q2 32,736,159 $170,877,689 -$7,216,025 $5.22 55
2022 Q1 34,109,145 $235,382,986 -$10,995,652 $6.90 64
2021 Q4 35,151,511 $437,636,391 -$26,977,029 $12.45 74
2021 Q3 35,967,344 $1,123,981,157 +$47,268,239 $31.25 61
2021 Q2 34,458,535 $986,644,054 +$52,903,899 $28.63 56
2021 Q1 32,543,650 $1,410,113,760 -$96,898,538 $43.33 60
2020 Q4 34,651,491 $2,474,382,581 +$136,089,518 $71.55 51
2020 Q3 33,322,061 $999,836,330 +$999,836,330 $30.13 38